NASDAQHealth CareHealth Information ServicesSnapshot 2026-07-23
Reading HTFL? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
HTFL represents a speculative growth investment. The current thesis state is cautious, as the company is loss-making and has shown weak financial performance recently.
The market seems to have priced in a justified valuation, with a premium compared to peers. However, there is a significant expectations gap, indicating that investors may be anticipating better future performance.
Management is focused on increasing revenue guidance and improving gross margins, but operating income has declined. The near-term risk of missing earnings remains moderate, especially given the company's recent performance relative to peers.
The future of HTFL hinges on the performance of sector bellwethers like VEEV, BTSG, and TEM. If these companies continue to perform well, it could provide a positive lift for HTFL; however, any negative guidance from them could pose risks.
In the next 1 to 3 years, HTFL's performance will depend on both its management execution and broader sector trends. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Confirming this guidance shows the company is on track for strong growth. It reflects management's confidence in revenue growth.
Confirms:Management says annual revenue guidance is still $228M-$232M for the next earnings call.
Disproves:Management cuts the annual revenue forecast to less than $228M.
Why it matters: If HeartFlow raises its revenue guidance, it shows strong growth momentum. This could boost investor confidence.
Confirms:The company raised its annual revenue guidance to over $232M.
Disproves:HeartFlow maintains or lowers its annual revenue guidance below $228M.
Why it matters: Confirming the revenue guidance of $228M-$232M shows strong growth momentum.
Confirms:Q2 revenue reported between $228M and $232M.
Disproves:Q2 revenue reported below $228M.
Why it matters: The earnings report will provide insights into revenue and margin trends.
Confirms one read:Earnings report shows strong revenue growth and margin improvements.
Confirms the other:Earnings report shows declining revenue or margins.
Why it matters: If healthcare sector growth picks up, it can benefit HeartFlow. This may improve its market position.
Confirms:Healthcare sector revenue growth speeds up above 10%.
Disproves:Healthcare sector revenue growth continues to decline below 5%.
Why it matters: Higher operating income shows better cost control. This is important for long-term growth.
Confirms:Operating income improves to less than -$29.5M in Q2 2026.
Disproves:Operating income worsens, landing more negative than -$29.5M in Q2 2026.
Why it matters: Higher operating income means better financial health. It can bring in more investors.
Confirms:HeartFlow shows operating income of more than -$20M.
Disproves:Operating income gets worse, dropping below -$30M.
Why it matters: This margin shows better cost control and makes more money. It helps financial health.
Confirms:HeartFlow reports a non-GAAP gross margin of 81% or higher.
Disproves:Non-GAAP gross margin remains below 75%.
Why it matters: A smaller operating loss shows better financial health and cost control.
Confirms:Operating loss was less than $29.5 million.
Disproves:Operating loss was worse than $29.5 million.
Why it matters: This margin shows better cost management and how well the company runs.
Confirms:Non-GAAP gross margin reported at or above 81%.
Disproves:Non-GAAP gross margin reported below 80%.
